FDA Brief

Warning letters Food

FDA warning letter to

Lysulin, Inc.

High riskIssued Sep 7, 2021Posted Sep 9, 2021Center for Food Safety and Applied Nutrition (CFSAN)

Lysulin, Inc. marketed diabetes and weight-loss supplements as unapproved drugs and misbranded products.

What happened

FDA reviewed Lysulin's website, Instagram and Facebook pages, and Amazon storefront in August 2021 and found claims that its supplements help manage, lower, prevent or reverse diabetes and blood sugar/A1c. FDA said these claims make the products drugs intended to treat disease, but they are not FDA-approved and lack adequate directions for lay use. FTC also reviewed the websites and demanded the company stop making disease claims without competent and reliable scientific evidence.

What FDA found

  1. The website, social media and Amazon claims show the supplements are intended to treat, prevent or mitigate diabetes and related conditions, so they are drugs under the law.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  2. The products are new drugs because they are not generally recognized as safe and effective for those uses and have no FDA approval.

    FD&C Act sections 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The products are misbranded because they do not have adequate directions for a layperson to use them safely for their intended disease uses.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]
  4. Selling the misbranded products in interstate commerce violates the Act.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]
  5. FTC says the company must stop claiming its products prevent, treat or cure diabetes unless it has competent and reliable scientific evidence from well-controlled human clinical studies.

    FTC Act, 15 U.S.C. ยง 41 et seq.

What FDA wants

FDA asks Lysulin to notify it in writing within 15 working days of the specific steps taken to address the violations and prevent recurrence, with supporting documents; if corrective actions cannot be completed in that time, the company must state why and when it will finish. FTC separately asks for notice within 15 working days of actions taken to address its concerns.

Who should pay attention

  • dietary supplement companies making blood sugar or diabetes claims
  • online retailers and marketplaces that list supplement products
  • advertising and social media teams using testimonial disease claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk